Related Experiment Video
Updated: Aug 19, 2026

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Published on: July 31, 2016
[The rate of antipyrine metabolism in cancer patients administered specific therapy]
Abstract:
Liver monooxygenase (MO) activity was evaluated in 31 children with oncological diseases. The enzyme activity was assessed by measuring the saliva half life of the test drug antipyrine. It was shown that MO activity is reduced in hepatitis, metastatic lesions of the liver, after long-term chemotherapy, combined treatment or progress of disease. Considerable individual variations in MO activity were observed even in cases of comparable pathologies during examinations. It is suggested that therapeutic response in patients with low MO liver levels could be optimized by appropriately stimulating said enzyme system prior to chemotherapy.
More Related Videos
10:38Simultaneous Quantification of Selected Kynurenines Analyzed by Liquid Chromatography-Mass Spectrometry in Medium Collected from Cancer Cell Cultures
Published on: May 9, 2020
06:21Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase